Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Clariom assays, 1/17

January 2017—Thermo Fisher Scientific’s two Clariom brand of assays, Clariom D Pico and Clariom S Pico, are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from coding and noncoding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include up-to-date content curated from a large number of public sequence databases, including RefSeq, Noncode, Ensembl, VEGA, lncRNAWiki, and RNA Central, among others.

iSpecimen, TriCore collaboration, 1/17

January 2017—iSpecimen and TriCore Reference Laboratories announced an agreement through which iSpecimen will serve as a TriCore channel partner for making patient biospecimens and associated data available for research. iSpecimen’s cloud-based technology will be used to tap into the flow of patients, specimens, and data running through the TriCore organization, matching researchers with a variety of annotated, de-identified samples.

Enzo launches two assays, 1/17

January 2017—Enzo Life Sciences introduced the PlaqPro Lp-PLA2 assay, a colorimetric readout assay that measures the activity of Lp-PLA2 in serum samples. The assay is designed to run on automated chemistry analyzers. Included in the kit are ready-to-use calibration standards and QC controls in order to measure a wide analytical range of 0.0–400.0 nmol/min/mL of Lp-PLA2 activity.

Biotheranostics, Syapse collaboration, 1/17

January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.

Wireless POC diagnostic device, 1/17

January 2017—Becton Dickinson launched its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus, and group A strep, with new traceability and secure patient health record documentation features and functionality.

Multiplexed leukemia translocation panel, 1/17

January 2017—EntroGen launched its Leukemia Translocation Panel, a multiplexed, one-step RT-PCR assay that detects 10 variants in six common leukemia-associated translocations simultaneously from total RNA isolated from blood or bone marrow. The assay is compatible with several leading multichannel real-time PCR instruments capable of detecting four commonly used fluorescent probes and produces results in 90 minutes.

FDA-cleared POC coagulation analyzer, 11/16

November 2016—Siemens Healthineers received FDA 510(k) clearance for its Xprecia Stride Coagulation Analyzer, a handheld, portable coagulation analyzer designed to deliver fast, reliable prothrombin time international normalized ratio testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin.

IVD CE mark for lateral flow assay analyzer, 11/16

November 2016—Alere announced it has achieved in vitro diagnostic CE marking in Europe for its Alere Reader, a diagnostic analyzer that can be used in point-of-care and laboratory settings. The Alere Reader will be available initially for use with the Alere BinNow Legionella and Streptococcus pneumonia antigen cards, with other lateral flow applications and assays to follow.

Inspirata acquires Precision Medicine Network, 11/16

November 2016—Cancer diagnostics and digital pathology workflow solution provider Inspirata has acquired the assets of Boston-based Precision Medicine Network. The acquisition includes Crosswalk Insight: Oncology, a precision medicine decision-support platform.

PCR master mix, 11/16

November 2016—Thermo Fisher Scientific launched the Applied Biosystems TaqPath ProAmp PCR Master Mix. The mixes are developed for high-throughput genotyping and copy number variation protocols requiring accurate results from samples containing PCR inhibitors and are designed to deliver sensitive and reproducible results from genomic DNA targets.

MARKETPLACE

TRENDING